• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Marc Kesselman

Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?

By Pallavi Madhiraju on May 4, 2026   Pharma & Biotech  

Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?

Purdue is gone, but its medicines remain. Knoa Pharma’s public health model now faces its hardest test: trust, access, and oversight.

Recent Posts

  • Why Ardent Health’s Bank of America fireside chat could matter for hospital sector sentiment
  • Can Siegfried turn Noramco’s controlled-substance expertise into a global CDMO edge?
  • Why Sequenex’s MedTech Innovator partnership matters for connected device startups
  • Could Cairn Surgical’s breast cancer locator cut repeat surgeries where wires fall short?
  • Purdue Pharma is gone. Can Knoa Pharma turn opioid profits into public health repair?
  • What Trividia Health’s TRUE METRIX correction reveals about diabetes device risk communication
  • Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?
  • Can UCB’s $2.2bn Candid Therapeutics deal reset the future of autoimmune therapy?
  • Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?
  • Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane
  • Could Kodiak’s KSI-101 become the first real biologic challenger in inflammatory eye disease?
  • Can Vector Science’s microneedle catheter patent crack one of oncology’s hardest delivery problems?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes